TTK Healthcare stock price jumped over 10 percent in the afternoon trade on March 21 to hit a fresh 52-week high of Rs 969.75 apiece, after the company approved sale of its human pharma division.
"The Board of Directors of TTK Healthcare in their meeting held on March 21, 2022, based on the recommendation of the audit committee, approved the proposal of sale / transfer of Human Pharma Division of the Company, as a going concern, on slump sale basis," the company said in an exchange filing.
"Pursuant to this decision, definitive agreements have been concluded with M/s BSV Pharma Private Limited (BS\4 and Miransa Limited, (an atflliate of Advent lnternational), with the closing of the transaction contemplated there under being subject to the approval of the shareholders by means of a postal ballot process and fulfilment of conditions precedent'that are customary in such transactions. Pursuant to the said agreement, the consideration will be settled by BSV to the Company to the extent of 74% in cash and 26% by way of allotment of equity shares," it added.
Catch all the market action on our live blog
At 1:45pm the scrip traded at Rs 880 apiece on the BSE, up 8.88 percent, while the benchmark Sensex was down 467.08 points or 0.81 percent at 57,396.85.
The stock touched an intraday high of Rs 969.75 and an intraday low of Rs 813. It was trading with volumes of 32,044 shares, compared to its five day average of 3,491 shares, an increase of 817.96 percent.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
